Strategic Acquisition Amaryllis Nucleics was acquired by Active Motif in January 2022, indicating an integration pathway and potential joint solutions that can be sold through an expanded epigenetics and RNA sequencing capabilities portfolio.

Integrated Offering Post-acquisition, there is a clear opportunity to position combined RNA sequencing services and 3′ DGE kits as a bundled or co-marketed solution to pharma, biotech, and research customers seeking faster, cost-efficient genomics workflows.

Cost and Speed Advantage The company emphasizes dramatically reducing time and cost in RNA sequencing, which can be pitched to laboratories facing high throughput needs, enabling upsell of premium sequencing services or scalable kits to oncology, pharmaceutical development, and food security research.

Small Team, Niche Focus With a single employee listed and a niche RNA sequencing technology, there is potential to target early adopters, grant-funded labs, and smaller CROs that value specialized, disruptive chemistry and rapid deployment in genomics projects.

Strategic Partnerships Leverage the Active Motif connection to pursue co-selling, channel partnerships, or license-for-service deals with organizations in epigenetics and diagnostics, expanding reach into precision medicine customers seeking integrated epi/transcriptomics solutions.